Crossref
What are the benefits and harms of immune checkpoint inhibitors (ICIs) in adults aged ≥ 65 years with early-stage resectable non-small cell lung cancer (NSCLC)?
Cochrane Clinical Answers · 09.11.2026
DOI: 10.1002/cca.4861 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cochrane Clinical Answers, online erschienen am 09.11.2026. Verfasst von Kwun M Fong. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Fong, K. M. (2026). What are the benefits and harms of immune checkpoint inhibitors (ICIs) in adults aged ≥ 65 years with early-stage resectable non-small cell lung cancer (NSCLC)?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4861
Vancouver
Fong KM. What are the benefits and harms of immune checkpoint inhibitors (ICIs) in adults aged ≥ 65 years with early-stage resectable non-small cell lung cancer (NSCLC)?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4861
BibTeX
@article{Fong2026,
author = {Fong, Kwun M},
title = {What are the benefits and harms of immune checkpoint inhibitors (ICIs) in adults aged ≥ 65 years with early-stage resectable non-small cell lung cancer (NSCLC)?},
journal = {Cochrane Clinical Answers},
year = {2026},
doi = {10.1002/cca.4861}
}
EUVIMED